1.92
-0.1(-4.95%)
Currency In USD
| Previous Close | 2.02 |
| Open | 2.17 |
| Day High | 2.86 |
| Day Low | 1.78 |
| 52-Week High | 130.39 |
| 52-Week Low | 1.78 |
| Volume | 2.14M |
| Average Volume | 218,570 |
| Market Cap | 1.01M |
| PE | -0.03 |
| EPS | -55.19 |
| Moving Average 50 Days | 7.93 |
| Moving Average 200 Days | 13.66 |
| Change | -0.1 |
If you invested $1000 in GRI Bio, Inc. (GRI) since IPO date, it would be worth $0.01 as of April 02, 2025 at a share price of $1.92. Whereas If you bought $1000 worth of GRI Bio, Inc. (GRI) shares 3 years ago, it would be worth $0.02 as of April 02, 2025 at a share price of $1.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GRI Bio Announces Pricing of $5.0 Million Public Offering
GlobeNewswire Inc.
Yesterday at 3:15 PM GMT
LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibro
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evalua
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
GlobeNewswire Inc.
Mar 31, 2025 12:00 PM GMT
Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, March 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NA